Bafna Pharmaceuticals Stock Sees Dip and Strong Sell Call from MarketsMOJO

Mar 21 2024 09:35 AM IST
share
Share Via
Bafna Pharmaceuticals, a microcap company in the pharmaceutical industry, has recently experienced a decline in its stock price. According to data from the stock market, the stock reached a 52-week low on March 21, 2024. MarketsMojo has given a Strong Sell call for the stock and it has underperformed the sector by 3.83% in today's trading session. However, there has been a positive trend reversal as the stock has gained after two consecutive days of falling. The stock has been trading at a stable range since the opening, with mixed short-term trends indicated by its moving averages. In comparison to the Sensex, Bafna Pharmaceuticals has shown a negative performance in the past year, suggesting that investors should carefully consider market trends before making any investment decisions.


Bafna Pharmaceuticals, a microcap company in the pharmaceutical industry, has recently seen a dip in its stock price. On March 21, 2024, the company's stock touched a 52-week low, according to data from the stock market.

MarketsMOJO, a leading stock analysis platform, has given a "Strong Sell" call for Bafna Pharmaceuticals. The stock has also underperformed the sector by 3.83% in today's trading session. However, there is a positive trend reversal as the stock has gained after two consecutive days of falling.

In today's trading, Bafna Pharmaceuticals opened with a gap up of 4.51% and touched an intraday high of Rs 83.61. The stock has been trading at this price since the opening, indicating a stable range.

When looking at the moving averages, Bafna Pharmaceuticals' stock is currently higher than the 5-day moving average but lower than the 20-day, 50-day, 100-day, and 200-day moving averages. This suggests a mixed trend in the short term.

In comparison to the Sensex, Bafna Pharmaceuticals has seen a negative performance of -12.40% in the past year, while the Sensex has shown a positive performance of 25.10%. This indicates that the company's stock has not performed as well as the overall market.

Overall, Bafna Pharmaceuticals' stock has seen a dip in its price and has been given a "Strong Sell" call by MarketsMOJO. Investors should carefully consider the company's performance and market trends before making any investment decisions.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News